Skip to main content

Advertisement

Table 1 Baseline characteristics of gastric cancer patients included in this study (N = 86)

From: Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy

Characteristics N (%)
Age at diagnosis, median (min–max) [IQ range] 61 (28–79) [53.6–67.6]
Gender
 Male 44 (51.2)
 Female 42 (48.8)
ECOG PS
 0 45 (52.3)
 1–2 41 (47.7)
Stage
 Locally advanced 36 (41.9)
 Metastatic 50 (58.1)
Previous surgery
 No 33 (38.4)
 Yes 53 (61.6)
Neoadjuvant/adjuvant chemotherapy
 No 61 (70.9)
 Yes 25 (29.1)
Lauren classification
 Intestinal 35 (40.7)
 Diffuse 41 (47.7)
 Mixed 10 (11.6)
Grade
 G2 21 (24.4)
 G3 65 (75.6)
Localization
 Esophagogastric junction 6 (7.0)
 Stomach 80 (93.0)
Agents (N)
 2 36 (41.9)
 3 50 (58.1)
Taxanes (first-line)
 No 39 (45.3)
 Yes 47 (54.7)